Adagrasib vs Calderasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
Adagrasib · Krazati
Marketed by Bristol-Myers Squibb and partners
NCT04685135 · Phase 3 · active, not recruiting
This was a randomized phase 3 trial of 453 people against an active comparator (docetaxel). The progression-free survival endpoint, reviewed by a blinded independent committee, was clearly met, but treatment was open-label, so it is graded below the highest tier.
Next expected readout: January 2027 · NCT06026410 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Adagrasib 5.49 months (95% CI 4.53 to 6.67) | Docetaxel 3.84 months (95% CI 2.73 to 4.73) (met)
Result source: NCT04685135
Calderasib
Developed by Merck & Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT06345729 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Adagrasib | Calderasib |
|---|---|---|
| PFS, median | —Trial running · NCT04613596 | —Trial running · NCT07554339 |
| OS, median | —Trial running · NCT04613596 | —Trial running · NCT07554339 |
| ORR | —Trial running · NCT04613596 | —Trial running · NCT07554339 |
| Duration of response, median | —Trial running · NCT04613596 | —Trial running · NCT07554339 |
PFS, median
- Adagrasib
- —Trial running · NCT04613596
- Calderasib
- —Trial running · NCT07554339
OS, median
- Adagrasib
- —Trial running · NCT04613596
- Calderasib
- —Trial running · NCT07554339
ORR
- Adagrasib
- —Trial running · NCT04613596
- Calderasib
- —Trial running · NCT07554339
Duration of response, median
- Adagrasib
- —Trial running · NCT04613596
- Calderasib
- —Trial running · NCT07554339
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Adagrasib: registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.
Calderasib: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adagrasib's landscape · Calderasib's landscape